No Data
CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
Cathie Wood's ARK Investment Bought 58K Shares of Crispr Therapeutics Today
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
吸猫西施 : Don't worry, Sister Wood blesses you.